Recently, tobacco company shareholders in Japan have called for the sale of their publicly listed pharmaceutical subsidiary, Torii Pharmaceutical Co, in order to boost performance and shareholder value.
LIM Advisors, a radical fund based in Hong Kong, has called on Japan Tobacco to divest 53% of its stake in a pharmaceutical company known for its anti-allergy products in a letter reviewed by Reuters. The fund is urging Japan Tobacco to use the proceeds to launch a ¥250bn ($1.94bn) share buyback.
In the letter, it was stated that there was no collaboration between the tobacco division of Japan and the pharmaceutical department, and there was no management of their professional knowledge regarding its development. LIM plans to submit their proposal at the annual shareholder meeting in March.
The Japan Tobacco Inc. has acknowledged receiving the proposal but stated that it cannot provide further details regarding the letter's content. Japan Tobacco told Reuters, "We are currently reviewing the contents and legal matters.
LIM declined to comment.
LIM Company holds less than 1% of shares in Japan Tobacco Inc. Their proposal is in response to Japanese regulatory authorities' disregard for the practice known as "parent-subsidiary listings", citing concerns that such practices may infringe upon the rights of small shareholders.
LIM is still pushing for the revision of the company bylaws to improve governance, including prohibiting executive retirees from Japan Tobacco from taking up positions in Torii Company, which is a type of golden parachute arrangement known as "amakudari".
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
